Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

NCT01152788 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

NETWORK

Sponsor class

Conditions

Melanoma

Interventions

DRUG: rIL-21
DRUG: Dacarbazine

Sponsor

NCIC Clinical Trials Group